Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution

Acquired drug resistance remains a major problem across oncogene-addicted cancers. Elucidation of mechanisms of resistance can inform rational treatment strategies for patients relapsing on targeted therapies while offering insights into tumor evolution. Here, we report acquired MET amplification as...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Jaime L., Shaverdashvili, Khvaramze, Mino-Kenudson, Mari, Digumarthy, Subba R., Do, Andrew, Liu, Audrey, Gainor, Justin F., Lennerz, Jochen K., Burns, Timothy F., Lin, Jessica J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624912/
https://www.ncbi.nlm.nih.gov/pubmed/37923925
http://dx.doi.org/10.1038/s41698-023-00464-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624912/
https://www.ncbi.nlm.nih.gov/pubmed/37923925
http://dx.doi.org/10.1038/s41698-023-00464-y

Ejemplares similares